Lyra therapeutics reports topline results from phase 3 enlighten 1 trial for lyr-210 in chronic rhinosinusitis

Enlighten 1 trial did not meet its primary endpoint company plans to evaluate full dataset and path forward watertown, mass., may 06, 2024 (globe newswire) -- lyra therapeutics, inc. (nasdaq: lyra) (“lyra” or the “company”), today announced topline results from the company's phase 3 enlighten 1 trial evaluating lyr-210 for the treatment of chronic rhinosinusitis (crs).
LYRA Ratings Summary
LYRA Quant Ranking